Bausch Health
Bausch Health Companies Inc is a world-wide specialty pharmaceutical, consumer health, and medical device company with a focus on branded products for the gastroenterology, hepatology, neurology and dermatology markets. The company reports revenue in five segments: Salix; International; Solta Medical; Diversified Products and Bausch + Lomb. It generates maximum revenue from the Bausch + Lomb segment.www.bauschhealth.com
46
MENTIONS
7
EPISODES
7
PODCASTS
Search complete. 46 mentions across 7 episodes found for "Bausch Health".
Oct 2, 2026
Aswath DamodaranHOST
The nature of intrinsic valuation often means that you're gonna be buying stocks that other people are selling.
Aswath DamodaranHOST
You're buying Valeant, you're buying Volkswagen, you're buying Deutsche Bank, because everybody's abandoned them.
Aswath DamodaranHOST
And you're gonna be selling stocks that everybody else is buying.
Aswath DamodaranHOST
So you're selling Amazon, you're selling Netflix.
Brian GlennGUEST
There's a, a massive amount that's been spent on R&D.
Brian GlennGUEST
There's white papers going way back in time where, actually, this is what created, uh, Valeant, um, years ago.
Brian GlennGUEST
It's that R&D has a negative ROI within the economy.
Brian GlennGUEST
So if you aggregate all the pharma spenders, you aggregate their R&D, and then you aggregate, um, the drugs they produce and what they sell those drugs for, there's a negative ROI in aggregate, and that was always the story.
Alex EdmansGUEST
And if you're shorting companies which might be fraudulent or which might be overinflated, you're also adding value.
Alex EdmansGUEST
So I know that short sellers get a lot of bad rep, and there are some short sellers which are manipulative, but if you short sell a company such as, say, Valeant Pharmaceuticals, which was engaging in unsustainable strategies, then this is actually better because this makes sure that those companies don't keep getting more capital, and then employees don't keep flocking to those firms.
David EdmondsHOST
But you've published all your research.
David EdmondsHOST
If these irrationalities exist, why doesn't a clever hedge fund just move in and take advantage of your findings?
Michael BrownHOST
Okay, why can't she buy the generic here? Because nobody's allowed to sell it here until the year 2028.
Michael BrownHOST
You see, Zyvaxin is sold in this country by Salix or Salix? It's owned by Bausch Health.
Michael BrownHOST
Now, when generic companies tried to bring out a cheaper version, Bausch sued them over their patents.
Michael BrownHOST
Then Bausch settled.
Tracey RyniecHOST
So that's Fox Factory Holdings, FOXF.
Tracey RyniecHOST
Okay, the second stock is Bausch Health.
Tracey RyniecHOST
BHC is the ticker.
Tracey RyniecHOST
They're a Canadian company headquartered in Quebec.
Tracey RyniecHOST
And they are a global pharmaceutical company in gastroenterology, hepatology, neuroscience, dermatology, dentistry, aesthetics, international pharmaceuticals, and eye health.
Tracey RyniecHOST
And that part is through the controlling interest in Bausch + Lomb, which many of us who wear contact lenses know is the eye contact lens and eye supplies [laughs] company.
Tracey RyniecHOST
Um, so they do, uh, parse out a lot of their earnings based on what Bausch Health is doing, and then they include Bausch + Lomb in there.
Tracey RyniecHOST
But you can get an idea, if you separate out the eye, the eye company and the controlling interest there, what the rest of the business is doing.
Tracey RyniecHOST
So that's Fox Factory Holdings, F-O-X-F.
Tracey RyniecHOST
Okay, the second stock is Bausch Health.
Tracey RyniecHOST
B-H-C is the ticker.
Tracey RyniecHOST
They're a Canadian company headquartered in Quebec, and they are a global pharmaceutical company in gastroenterology, hepatology, neuroscience, dermatology, dentistry, aesthetics, and international pharmaceuticals and eye health.
Tracey RyniecHOST
And that part is through the controlling interest in Bausch and Lomb, which many of us who wear contact lenses know is the eye contact lens and eye supplies company.
Tracey RyniecHOST
So they do parse out a lot of their earnings based on what Bausch Health is doing, and then they include Bausch & Lomb in there, but you can get an idea if you separate out the eye company and the controlling interest there, what the rest of the business is doing.
Tracey RyniecHOST
So they are a little bit bigger, but I still consider this a small cap, market cap of just $2.2 billion.
Tracey RyniecHOST
And these shares plunged in 2022 and have been just down on their luck ever since.
Matthew PechHOST
The barbarians are at the gate, and they brought Bill Ackman.
Matthew PechHOST
[upbeat music] In April 2014, a company called Valeant Pharmaceuticals launches an unsolicited hostile takeover attempt of Allergan, kicking off a years-long battle for the company.
Matthew PechHOST
This is the inflection point for Allergan's existence as a company.
Matthew PechHOST
Before, a relatively calm and quiet company with a weird portfolio, and after, a corporation riddled with activist drama- Legal battles, even political intrigue, all of it starts with this M&A takeover with Valeant.
Alex KesinHOST
So who was this mysterious suitor, Valeant? In every philosophical respect, this company was Allergan's exact opposite.
Alex KesinHOST
Run by Michael Pearson, a former McKinsey consultant, surprise, surprise, Valeant focused on products with limited competition.
Alex KesinHOST
It was effectively a highly focused tax optimization scheme, doing shenanigans like merging with a Canadian company to get their tax rate down.
Alex KesinHOST
Most relevant for your story, though, and perhaps what they became most famous for, it thought R&D could and should be cut to the bone.